Communicable diseases

Our Communicable diseases unit is focused on a targeted portfolio of programs and partnerships that build on our decades of work in communicable diseases and have potential to save and improve lives.

By harnessing our deep expertise and passion for science, our team works to tackle viral and bacterial threats, creating hope for a healthier, safer world.

From invasive E. coli disease to HIV to tuberculosis, communicable diseases are some of the most entrenched health challenges on the planet.

Focus areas

Female doctor examining petri dish at desk in medical room

Communicable diseases

Extraintestinal pathogenic E. coli (ExPEC)

May 21, 2024

Close up of lab tech transferring sample into vial

Communicable diseases

Tuberculosis

May 21, 2024

Communicable diseases

Leprosy

May 21, 2024

Communicable diseases

HIV

May 21, 2024

Latest news

Communicable diseases & vaccines

European Commission Approves Expanded Use of HIV-1 Therapy
EDURANT® (rilpivirine) in Younger Pediatric Patients

October 28, 2024

Belgium

Communicable diseases & vaccines

U.S. FDA Approves EDURANT® PED (rilpivirine) for Certain Pediatric Patients Living with HIV-1

March 19, 2024

United States

Communicable diseases & vaccines

Janssen Enters into Agreement with Sanofi to Advance Potential First-In-Class Vaccine Program

October 3, 2023

United States

Communicable diseases & vaccines

Janssen and Global Partners to Discontinue Phase 3 Mosaico HIV Vaccine Clinical Trial

January 18, 2023

Communicable diseases & vaccines

World Health Organization Updated Emergency Use Listing Recommends Johnson & Johnson COVID-19 Vaccine for Booster Use

April 6, 2022

United States